The management of nausea and vomiting of pregnancy

J Obstet Gynaecol Can. 2002 Oct;24(10):817-31; quiz 832-3.
[Article in English, French]

Abstract

Objectives: To review the evidence-based management of nausea and vomiting of pregnancy (NVP) and hyperemesis gravidarum.

Evidence: MEDLINE and Cochrane database searches were performed using the medical subject headings (MeSH) of treatment, nausea, vomiting, pregnancy, and hyperemesis gravidarum. The quality of evidence reported in these guidelines has been described using the Evaluation of Evidence criteria outlined in the Report of the Canadian Task Force on the Periodic Health Exam.

Benefits: NVP has a profound effect on women's health and quality of life during pregnancy, as well as a financial impact on the health care system, and its early recognition and management are recommended. (III-B) COST: Costs, including hospitalizations, additional office visits, and time lost from work, may be reduced if NVP is treated early.

Publication types

  • Guideline
  • Practice Guideline

MeSH terms

  • Algorithms
  • Anti-Inflammatory Agents / therapeutic use
  • Antiemetics / therapeutic use
  • Complementary Therapies / methods
  • Complementary Therapies / standards
  • Cost of Illness
  • Decision Trees
  • Evidence-Based Medicine
  • Female
  • Humans
  • Hyperemesis Gravidarum / economics
  • Hyperemesis Gravidarum / psychology
  • Hyperemesis Gravidarum / therapy*
  • Life Style
  • Nausea / economics
  • Nausea / psychology
  • Nausea / therapy*
  • Obstetrics / methods*
  • Obstetrics / standards
  • Pregnancy
  • Pregnancy Complications / economics
  • Pregnancy Complications / psychology
  • Pregnancy Complications / therapy*
  • Pregnancy Outcome / epidemiology
  • Prenatal Care / methods*
  • Prenatal Care / standards
  • Pyridoxine / therapeutic use
  • Quality of Life
  • Steroids
  • Vomiting / economics
  • Vomiting / psychology
  • Vomiting / therapy*

Substances

  • Anti-Inflammatory Agents
  • Antiemetics
  • Steroids
  • Pyridoxine